Abstract | BACKGROUND: OBSERVATIONS: Four patients with NSF were treated with UV-A1 phototherapy at a tertiary medical center from 2005 through 2007. To our knowledge, it is unique to this series that all patients were receiving hemodialysis before, during, and after therapy with UV-A1. All experienced improvement in the degree of induration, and 2 experienced improvement in mobility of the hands and legs. Total treatments ranged from 22 treatments (with a cumulative dose of 1855 J/cm(2)) to 50 treatments (total UV-A1 exposure, 3850 J/cm(2)). No adverse events were observed. CONCLUSIONS: Although no patient had complete resolution of indurated plaques, the improvement was substantial. For 2 patients, it resulted in a resumption of hand and leg mobility. As a result, UV-A1 therapy may represent a treatment for NSF when kidney transplantation is not an option or is delayed. Limitations of this study include the lack of a controlled trial, lack of quantification of gadolinium levels within tissue, and the lack of a defined grading scale for NSF severity.
|
Authors | Kien T Tran, Heidi B Prather, Clay J Cockerell, Heidi Jacobe |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 145
Issue 10
Pg. 1170-4
(Oct 2009)
ISSN: 1538-3652 [Electronic] United States |
PMID | 19841406
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Biopsy, Needle
- Dose-Response Relationship, Radiation
- Female
- Follow-Up Studies
- Gadolinium
(adverse effects)
- Humans
- Immunohistochemistry
- Kidney Failure, Chronic
(chemically induced, complications, pathology, therapy)
- Middle Aged
- Nephrogenic Fibrosing Dermopathy
(chemically induced, complications, pathology, radiotherapy)
- Radiation Dosage
- Recurrence
- Renal Dialysis
(methods)
- Risk Assessment
- Sampling Studies
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Ultraviolet Therapy
(methods)
|